海普瑞(09989.HK)曾重越上市价 料中绩最多赚6亿人币
海普瑞(09989.HK)(002399.SZ)料中期纯利最多增长10%,A股今早曾高见28.63元人民币,现造28.32元人民币,急涨8.8%,成交2,512万股;H股曾重越上市价18.4元,最高见18.54元,现造18.12元,回升3.1%,成交增至1,000万股,已远超昨天全日成交量452万股。
海普瑞预计,上半年纯利介乎5.46亿至6.01亿人民币,按年增长0%至10%,主要受惠於由於垂直一体化肝素特许经营产业链受依诺肝素注射液制剂业务驱动业绩快速增长,原料药业务毛利率也实现大幅上升,CDMO业务收入增长、毛利额及毛利率增长,边际效应显着;及非经常性损益下降75%-85%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.